FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRMLFree Report) – Stock analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Tourmaline Bio in a research report issued on Sunday, May 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($3.15) per share for the year, up from their prior estimate of ($3.20). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share.

Other research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Tourmaline Bio in a research report on Monday. Wedbush raised their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Friday, March 14th. Chardan Capital reissued a “buy” rating and issued a $70.00 target price on shares of Tourmaline Bio in a report on Monday. Finally, Lifesci Capital initiated coverage on Tourmaline Bio in a research note on Monday, February 24th. They set an “outperform” rating and a $58.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $49.33.

View Our Latest Stock Analysis on TRML

Tourmaline Bio Stock Up 5.8 %

Shares of Tourmaline Bio stock opened at $15.39 on Wednesday. Tourmaline Bio has a 52 week low of $11.56 and a 52 week high of $29.79. The firm’s 50 day moving average is $15.36 and its two-hundred day moving average is $18.95. The firm has a market capitalization of $395.29 million, a P/E ratio of -5.46 and a beta of 2.11.

Tourmaline Bio (NASDAQ:TRMLGet Free Report) last released its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.02.

Hedge Funds Weigh In On Tourmaline Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers grew its stake in shares of Tourmaline Bio by 2.1% in the 4th quarter. Rhumbline Advisers now owns 35,591 shares of the company’s stock valued at $722,000 after purchasing an additional 718 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Tourmaline Bio by 3.4% during the fourth quarter. SG Americas Securities LLC now owns 34,812 shares of the company’s stock worth $706,000 after purchasing an additional 1,140 shares during the period. Invesco Ltd. lifted its holdings in shares of Tourmaline Bio by 10.8% during the fourth quarter. Invesco Ltd. now owns 12,155 shares of the company’s stock worth $247,000 after purchasing an additional 1,181 shares during the period. Tower Research Capital LLC TRC grew its position in Tourmaline Bio by 297.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company’s stock valued at $33,000 after buying an additional 1,232 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new position in Tourmaline Bio in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

(Get Free Report)

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

Read More

Earnings History and Estimates for Tourmaline Bio (NASDAQ:TRML)

Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.